Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Exon 53 of dystrophin pre-mRNA is one of 79 protein-coding exons in the DMD gene pre-mRNA that, when correctly spliced, enables the production of full-length dystrophin—a structural protein essential for muscle fiber stability. In Duchenne muscular dystrophy, certain exon deletions disrupt the reading frame, causing the absence of functional dystrophin. Drugs such as viltolarsen and golodirsen are designed to bind exon 53 in the pre-mRNA and induce its skipping during splicing, restoring the mRNA's reading frame and enabling the synthesis of a truncated but functional dystrophin protein, thereby providing a molecularly guided therapy for a subset of DMD patients
Antisense oligonucleotide-mediated exon skipping: Synthetic oligonucleotides bind to exon 53 of dystrophin pre-mRNA, hiding it from the spliceosome and causing its exclusion from the mature mRNA, restoring the transcript’s reading frame and enabling production of a truncated but partially functional dystrophin protein
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Exon 53 of dystrophin pre-mRNA.